Prior to the advent of sodium/glucose cotransporter 2 (SGLT2) inhibitors, the treatment of diabetic kidney disease (DKD) remained relatively unchanged for close to 2 decades. The mainstay of therapy centered on aggressive glycemic control in conjunction with managing hypertension with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers. Recently, multiple randomized controlled trials have unequivocally demonstrated the cardiovascular and renoprotective benefits of SGLT2 inhibitors, revolutionizing the management of diabetes and DKD (Table 1).